Odaily News Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a U.S. listed company, announced yesterday that the company's board of directors approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy. Enlivex CEO Oren Hershkovitz said that with the growing demand for Bitcoin and its increasing acceptance as a recognized medium of exchange, the company needs to reserve such strong and diverse assets. And with the recent approval of the Bitcoin ETF and the increasing support of institutional investors, Bitcoin can provide the company with potential functional value storage and inflation hedge for standard currencies. It is reported that Enlivex is a clinical-stage macrophage reprogramming immunotherapy company. (Globenewswire)